Alternative approaches to antifungal therapies

Experimental Dermatology

Volumn 21, Issue 10, 2012, Pages 778-782

  Mehra, Tarun ^a   Köberle, Martin ^a   Braunsdorf, Christina ^a   Mailänder Sanchez, Daniela ^a   Borelli, Claudia ^a   Schaller, Martin ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Antifungal therapies; Antimicrobial peptides; Cathelicidin; Defensin; Inhibitors; Sap

Indexed keywords

ANTIFUNGAL AGENT; ANTILEUKOPROTEASE; ANTIMICROBIAL CATIONIC PEPTIDE; ASPARTIC PROTEINASE; CALGRANULIN; CATHELICIDIN; CHITOTRIOSIDASE; DEFENSIN; DERMCIDIN; HISTATIN; LACTOFERRIN; LYSOZYME; RIBONUCLEASE 7; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; CELL PERMEABILIZATION; DRUG MECHANISM; DRUG TARGETING; FUNGAL MEMBRANE; FUNGAL VIRULENCE; HUMAN; NONHUMAN;

ANIMALS; ANTIFUNGAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CANDIDA ALBICANS; DEFENSINS; DERMATOMYCOSES; HEXOSAMINIDASES; HISTATINS; HUMANS; LACTOFERRIN; LEUKOCYTE L1 ANTIGEN COMPLEX; MURAMIDASE; PEPTIDES; RIBONUCLEASES; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; VIRULENCE FACTORS;

EID: 84871799683     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/exd.12004     Document Type: Article

References (55)

1. Lalla R V, Latortue M C, Hong C H et al. Support Care Cancer 2010: 18: 985-992.
2. Chai L Y, Netea M G, Vonk A G et al. Med Mycol 2009: 47: 227-236.
3. Braff M H, Bardan A, Nizet V et al. J Invest Dermatol 2005: 125: 9-13.
4. Harder J, Schroder J M. J Biol Chem 2002: 277: 46779-46784.
5. Kamaya T. Mycopathol Mycol Appl 1970: 42: 197-207.
6. Papini M, Simonetti S, Franceschini S et al. Arch Dermatol Res 1982: 272: 167-170.
7. van de Merwe J P, Lindemans J, Mol G J. Hepatogastroenterology 1980: 27: 130-134.
8. Naglik J R, Challacombe S J, Hube B. Microbiol Mol Biol Rev 2003: 67: 400-428.
9. Wu T, Samaranayake L P, Leung W K et al. J Med Microbiol 1999: 48: 721-730.
10. Ibrahim H R, Imazato K, Ono H. J Agric Food Chem 2011: 59: 10336-10345.
11. Escott G M, Adams D J. Infect Immun 1995: 63: 4770-4773.
12. Kzhyshkowska J, Gratchev A, Goerdt S. Biomark Insights 2007: 2: 128-146.
13. Gordon-Thomson C, Kumari A, Tomkins L et al. Cell Mol Life Sci 2009: 66: 1116-1125.
14. Samaranayake Y H, Samaranayake L P, Wu P C et al. Apmis 1997: 105: 875-883.
15. Orsi N. Biometals 2004: 17: 189-196.
16. Tomee J F, Hiemstra P S, Heinzel-Wieland R et al. J Infect Dis 1997: 176: 740-747.
17. Abtin A, Eckhart L, Glaser R et al. J Invest Dermatol 2010: 130: 2423-2430.
18. Murthy A R, Lehrer R I, Harwig S S et al. J Immunol 1993: 151: 6291-6301.
19. Edgerton M, Koshlukova S E. Adv Dent Res 2000: 14: 16-21.
20. Selsted M E, Ouellette A J. Nat Immunol 2005: 6: 551-557.
21. Duits L A, Ravensbergen B, Rademaker M et al. Immunology 2002: 106: 517-525.
22. Schroeder B O, Wu Z, Nuding S et al. Nature 2011: 469: 419-423.
23. Harder J, Bartels J, Christophers E et al. Nature 1997: 387: 861.
24. Hertz C J, Wu Q, Porter E M et al. J Immunol 2003: 171: 6820-6826.
25. Sorensen O E, Thapa D R, Rosenthal A et al. J Immunol 2005: 174: 4870-4879.
26. Harder J, Schroder J M. J Leukoc Biol 2005: 77: 476-486.
27. Harder J, Bartels J, Christophers E et al. J Biol Chem 2001: 276: 5707-5713.
28. Krishnakumari V, Rangaraj N, Nagaraj R. Antimicrob Agents Chemother 2009: 53: 256-260.
29. Zaiou M, Nizet V, Gallo R L. J Invest Dermatol 2003: 120: 810-816.
30. McCormick T S, Weinberg A. Periodontol 2000 2000: 54: 195-206.
31. Murakami M, Lopez-Garcia B, Braff M et al. J Immunol 2004: 172: 3070-3077.
32. Rieg S, Steffen H, Seeber S et al. J Immunol 2005: 174: 8003-8010.
33. Frohm M, Agerberth B, Ahangari G et al. J Biol Chem 1997: 272: 15258-15263.
34. Lopez-Garcia B, Lee P H, Gallo R L. J Antimicrob Chemother 2006: 57: 877-882.
35. Lopez-Garcia B, Lee P H, Yamasaki K et al. J Invest Dermatol 2005: 125: 108-115.
36. Kamysz W, Nadolski P, Kedzia A et al. Pol J Microbiol 2006: 55: 303-307.
37. Maurya I K, Pathak S, Sharma M et al. Peptides 2011: 32: 1732-1740.
38. Semlali A, Leung K P, Curt S et al. Peptides 2011: 32: 859-867.
39. Schittek B, Hipfel R, Sauer B et al. Nat Immunol 2001: 2: 1133-1137.
40. Steffen H, Rieg S, Wiedemann I et al. Antimicrob Agents Chemother 2006: 50: 2608-2620.
41. Wagener J, Schneider J J, Baxmann S, Kalbacher H, Borelli C, Nuding S et al. J Invest Dermatol 2012: doi:10.1038.
42. White T C, Marr K A, Bowden R A. Clin Microbiol Rev 1998: 11: 382-402.
43. White T C. Antimicrob Agents Chemother 1997: 41: 1482-1487.
44. Mandal S M, Migliolo L, Franco O L et al. Peptides 2011: 32: 1741-1747.
45. Bein M, Schaller M, Korting H C. Curr Drug Targets 2002: 3: 351-357.
46. Borelli C, Ruge E, Lee J H et al. Proteins 2008: 72: 1308-1319.
47. Watts H J, Cheah F S, Hube B et al. FEMS Microbiol Lett 1998: 159: 129-135.
48. Bektić J, Lell C P, Fuchs A et al. FEMS Immunol Med Microbiol 2001: 31: 65-71.
49. Arribas J R, Hernandez-Albujar S, Gonzalez-Garcia J J et al. AIDS 2000: 14: 979-985.
50. Hoegl L, Thoma-Greber E, Rocken M et al. Mycoses 1998: 41: 321-325.
51. Schaller M, Krnjaic N, Niewerth M et al. J Med Microbiol 2003: 52: 247-249.
52. Borg-von Zepelin M, Meyer I, Thomssen R et al. J Invest Dermatol 1999: 113: 747-751.
53. Gauwerky K, Borelli C, Korting H C. Drug Discov Today 2009: 14: 214-222.
54. De Bernardis F, Liu H, O'Mahony R et al. J Infect Dis 2007: 195: 149-157.
55. Kuipers M E, de Vries H G, Eikelboom M C et al. Antimicrob Agents Chemother 1999: 43: 2635-2641.